Dr. Kalinsky on Updates from the TAILORx Trial in HR-Positive/HER2-Negative Breast Cancer

In Partnership With:

Partner | Cancer Centers | <b>Winship</b>

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

Kevin Kalinsky, MD, MS, associate professor, the Department of Hematology and Medical Oncology, Emory University School of Medicine, director, the Glenn Family Breast Center, Breast Medical Oncology, Winship Cancer Institute of Emory University, discusses updates from the phase 3 TAILORx trial (NCT00310180) in patients with hormone receptor (HR)–positive or HER2-negative breast cancer with node-negative disease.

TAILORx utilized the Oncotype DX Breast Recurrence Score to investigate the relative value of hormone therapy with or without chemotherapy in women with intermediate-risk breast cancer.

Data from TAILORx continue to be a practice-changing, with updates still emerging from the study, Kalinsky says. Patients who had a recurrence score greater than 25 achieved better outcomes with chemotherapy followed by endocrine therapy, compared with patients who were administered endocrine therapy alone, Kalinsky explains. Notably, updated data have shown that non-Hispanic Black patients had worse outcomes vs other races and ethnicities, Kalinsky adds.

Additionally, this trial helped introduce the idea of using the 21-Gene Recurrence Score and Clinical-Pathological Features [RSClin] in combination with recurrence score for this patient population, Kalinsky continues. RSClin evaluates patients based on clinical risk and pathologic features, Kalinsky says. By using these tools, clinicians can better individualize risk and identify the potential benefit from chemotherapy, Kalinsky concludes.